Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Isotretinoin

Drug and asset intelligence for Isotretinoin with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Upsher Smith Labs →

Recent signals(2)

ClinicalAugust 12, 2026

Phase 2 Study of Isotretinoin vs. Doxycycline for Acneiform Rash in Cancer Patients

A phase 2 study is underway to evaluate the efficacy of isotretinoin compared to doxycycline for treating acneiform rash in patients receiving MAPK pathway-targeted therapies.

RegulatoryJune 23, 2026

FDA Approval Status Update for Isotretinoin by Upsher Smith Labs

The FDA has granted an Approval Pending (AP) status for the isotretinoin application ANDA213571 submitted by Upsher Smith Labs.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Upsher Smith Labs — Isotretinoin

June 23, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Dermatology →

Dermatology · Acne →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.